Renovaro, Inc. (ENOB)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Renovaro, Inc. (ENOB)
Go deeper and ask any question about ENOB
Company Performance
Current Price
as of Sep 13, 2024$0.66
P/E Ratio
N/A
Market Cap
$96.62M
Description
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Metrics
Overview
- HQLos Angeles, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerENOB
- Price$0.655+5.51%
Trading Information
- Market Cap$96.62M
- Float55.47%
- Average Daily Volume (1m)303,136
- Average Daily Volume (3m)705,069
- EPS-$1.05
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$51.21M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$8.74M
- EV$293.08M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings